Synonym: benign mucous membrane pemphigoid, Brunsting-Perry disease, epidermolysis bullosa acquisita
Cicatricial pemphigoid (CP) refers to a group of rare chronic autoimmune blistering diseases affecting mainly mucous membranes (including the conjunctiva). A few patients have skin involvement which is usually around the head and neck or sites of skin trauma. Some patients have only eye involvement and a few only skin involvement. It is characterised by scarring of mucous membranes which can lead to complications such as blindness and supraglottic stenosis.
There is variety in the way CP presents clinically and some variety in the pathophysiological detail between patients. It can be difficult to distinguish from other autoimmune blistering diseases which may have mucosal involvement (for example, bullous pemphigoid). It is important to recognise the distinctive pattern of clinical features when making the diagnosis.
- Add notes to any clinical page and create a reflective diary
- Automatically track and log every page you have viewed
- Print and export a summary to use in your appraisal
Cicatricial pemphigoid (CP) is an autoimmune disease with autoantibodies found in the lamina lucida (occasionally extending into the lamina densa) at the epidermal-dermal junction. These antibodies recognise a variety of antigenic components of the epithelial membrane. Bullous pemphigoid antigens 1 and 2 (BPAG 1 and 2) have been identified in CP along with a variety of others. There is a poor correlation between the particular circulating autoantibody and the clinical presentation.
- Cicatricial pemphigoid (CP) is rare although precise figures for incidence are unknown.
- There is an association between human leucocyte antigen DQB1*0301 and CP in the white population of the United States of America.
- The reported incidence in European countries is about 1 per million per year.
- The estimated incidence of ocular CP is between 1 in 8,000 and 1 in 46,000. The real frequency of the disease is probably higher because of diagnostic difficulty.
- It appears to be about twice as common in women.
- It occurs in older patients with an average age of between 62 and 64 years at onset.
Cicatricial pemphigoid (CP) typically causes persistent and painful ulceration on mucous membranes, with progressive scarring. Oral ulceration can present a diagnostic problem. The main sites and types of involvement are:
- Painful and recurrent erosions present anywhere in the mouth, starting as blisters.
- The gingivae are most commonly involved, but palate and buccal mucosa are frequently affected too.
- Dysphagia and hoarseness may signal involvement of the oropharynx.
- Swallowing may be impaired by progressive scarring leading to oesophageal stenosis.
- Subglottic stenosis may compromise the airway (tracheostomy then required).
- This may manifest first with epistaxis.
- Painful, scarring erosions persist and alert to underlying disease
- This occurs in as many as a third of patients with CP.
- Intense, often generalised, pruritus accompanies skin involvement (tense blisters or erosions on normal or erythematous skin).
- Head and neck involvement is common. This may occur without mucosal involvement in, typically, elderly men (Brunsting-Perry variant).
- Vesicles may be tense and haemorrhagic with scars and milia forming afterwards.
- Alopecia follows scalp involvement.
- Genitalia and perianal mucosae:
- Typically painful with pruritus and scarring.
- Involves the clitoris, labia, glans and shaft of penis.
- Bullous pemphigoid
- Epidermolysis bullosa
- Erythema multiforme
- Linear IgA dermatosis
- Desquamative gingivitis
- Histology, direct immunofluorescence (DIF) and indirect immunofluorescence (IDIF) are used to diagnose cicatricial pemphigoid (CP). However differentiation from similar blistering diseases (particularly bullous pemphigoid) is on clinical grounds.
- Imaging may be required to investigate the upper airway and oesophagus.
Management of cicatricial pemphigoid (CP) may involve different modalities of treatment depending on the pattern of involvement. It is a difficult disease to manage.This may involve:
- Medical management:
- The aim is to suppress blistering and scarring.
- Lowest doses of drugs should be used to minimise side-effects. Drugs used to suppress inflammation include:
- Triamcinolone used topically for mild gingival and buccal disease.
- Dapsone can be helpful in ocular and mucosal disease.
- Prednisolone is often required with attendant complications.
- Azathioprine may be needed to spare steroid use.
- Other agents such as cyclophosphamide, cyclosporin, sulfasalazine, etanercept and mycophenolate are also used.
- Surgical management may be required particularly for:
- A coordinated team approach. Other referrals are helpful to a variety of specialties determined by the particular pattern of disease and complications:
- Dietary advice: soft, non-acidic foods, adequate calcium and vitamin D intake.
- Dental advice for gingival and buccal complications.
- Physiotherapy. This should encourage and facilitate an active and as near-normal lifestyle as possible. Exercise, avoiding trauma, is helpful (typically swimming is recommended).
- Ophthalmology for eye complications - for example, surgery and contact lenses may be indicated.
- Specialist dermatology advice is usually required for what is a rare and difficult disease.
- ENT referral may be required for diagnosis (endoscopy) and treatment.
- Gynaecology referral may be needed when there is genital involvement.
- Gastroenterology advice, usually for oesophageal complications.
- Endocrinology referral may help with advice on prevention of steroid complications.
The disease is chronic, progressive and difficult to treat. There may be exacerbations and remissions with waning disease activity. The risk of malignancy, particularly with anti-epilgrin cicatricial pemphigoid (CP), is significant.
Further reading & references
- Foster CS; Cicatricial pemphigoid. Trans Am Ophthalmol Soc. 1986;84:527
- Hoang, Robin H, Demers PE, et al; Pure ocular cicatricial pemphigoid. A distinct immunopathologic subset of cicatricial pemphigoid. Ophthalmology. 1999 Feb;106(2):355
- Rashid KA, Gurcan HM, Ahmed AR; Antigen specificity in subsets of mucous membrane pemphigoid. J Invest Dermatol. 2006 Dec;126(12):2631
- Bruch, Hertl M, Ruzicka T; Mucous membrane pemphigoid: clinical aspects, immunopathological features and therapy. Eur J Dermatol. 2007 May
- Delgado JC, Turbay D, Yunis EJ, et al; A common major histocompatibility complex class II allele HLA Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8569
- Endo H, Rees TD, Kuyama K, et al; Clinical and diagnostic features of mucous membrane pemphigoid. Compend Contin Educ Dent. 2006 Sep;27(9):512
- Grattan CE, Scully C; Oral ulceration: a diagnostic problem. Br Med J (Clin Res Ed). 1986 Apr 26;292(6528):1093
- Sgrulletta R, Lambiase A, Micera A, et al; Corneal ulcer as an atypical presentation of ocular cicatricial pemphigoid. Eur J Ophthalmol. 2007 Jan
- Iwata H, Aoyama Y, Esaki C, et al; Cicatricial pemphigoid with prominent alopecia. Eur J Dermatol. 2007 Jun 1;17(4):339
- Sadler E, Lazarova Z, Sarasombath P, et al; A widening perspective regarding the relationship between anti J Dermatol Sci. 2007 Jul;47(1):1
- Letko E, Gurcan HM, Papliodis GN, et al; Relative risk for cancer in mucous membrane pemphigoid associated with antibodies to the beta4 integrin subunit. Clin Exp Dermatol. 2007 May 25;.
- Schrader S, Notara M, Beaconsfield M, et al; Tissue engineering for conjunctival reconstruction: established methods and Curr Eye Res. 2009 Nov;34(11):913-24.
- Fatahzadeh M, Radfar L, Sirois DA; Dental care of patients with autoimmune vesiculobullous diseases: case reports and literature review. Quintessence Int. 2006 Nov
- Schornack MM, Baratz KH; Ocular cicatricial pemphigoid: the role of scleral lenses in disease management. Cornea. 2009 Dec;28(10):1170-2.
- Chew HF, Ayres BD, Hammersmith KM, et al; Boston Keratoprosthesis Outcomes and Complications. Cornea. 2009 Aug 29.
- McKay M; Disorders of the female genitalia. West J Med. 1996 Jun;164(6):520.
|Original Author: Dr Richard Draper||Current Version: Dr Richard Draper|
|Last Checked: 22/01/2010||Document ID: 7010 Version: 4||© EMIS|
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.